Rates of progression in mild cognitive impairment and early Alzheimer's disease

Neurology

Volumn 59, Issue 7, 2002, Pages 1034-1041

  Storandt, Martha ^a   Grant, Elizabeth A ^a   Miller, J Philip ^a   Morris, John C ^a  

^a Alzheimer Disease Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NURSING HOME; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; SCORING SYSTEM;

EID: 0037044231     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.7.1034     Document Type: Article

References (66)

1. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
2. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;277:806-812.
3. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991;39:932-941.
4. Bowler JV, Munoz DG, Merskey H, Hachinski V. Factors affecting the age of onset and rate of progression of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998;65:184-190.
5. Diesfeldt HFA, van Houte LR, Moerkens RM. Duration of survival in senile dementia. Acta Psychiatr Scand 1986;73:366-371.
6. Heyman A, Peterson B, Fillenbaum G, Pieper C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology 1996;46:656-660.
7. Heyman A, Peterson B, Fillenbaum G, Pieper C. Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII. Neurology 1997;48:1304-1309.
8. Knopman DS, Berg JD, Thomas R, et al. Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology 1999;52:714-718.
9. Farrer LA, Cupples LA, van Duijn CM, et al. Rate of progression of Alzheimer's disease is associated with genetic risk. Arch Neurol 1995;52:918-923.
10. Swearer JM, O'Donnell BF, Ingram SM, Drachman DA. Rate of progression in familial Alzheimer's disease. J Geriatr Psychiatry Neurol 1996;9:22-25.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-1328.
12. Dal Forno G, Rasmusson DX, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996;53:345-350.
13. Koivisto AM, Lempiainen P, Koivisto K, et al. Apolipoprotein E phenotype alone does not influence survival in Alzheimer's disease: a population-based longitudinal study. Neuroepidemiology 2000;19:327-332.
14. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E ε4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47:440-443.
15. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620.
16. Burns A, Lewis G, Jacoby R, Levy R. Factors affecting survival in Alzheimer's disease. Psychol Med 1991;21:363-370.
17. Butters MA, Lopez OL, Becker JT. Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline. Neurology 1996;46:687-692.
18. Kaszniak AW, Fox J, Gandell DL, et al. Predictors of mortality in presenile and senile dementia. Ann Neurol 1978;3:246-252.
19. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
20. Yesavage JA, Brooks JO, Taylor J, Tinklenberg J. Development of aphasia, apraxia, and agnosia and decline in Alzheimer's disease. Am J Psychiatry 1993;150:742-747.
21. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol 1997;54:878-885.
22. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analysis from the Predictors Study. Neurology 1994;44:2300-2307.
23. Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol 1995;50:M49-M55.
24. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease: "how far" rather than "how fast" best predicts the course. Arch Neurol 1990;47:851-856.
25. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41:1006-1009.
26. Stern Y, Tang MX, Denaro J, Mayeux R. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995;37:590-595.
27. Luchins DJ, Cohen D, Hanrahan P, et al. Are there clinical differences between familial and nonfamilial Alzheimer's disease? Am J Psychiatry 1992;149:1023-1027.
28. Mann UM, Mohr E, Gearing M, Chase TN. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry 1992;55:956-959.
29. Boller F, Becker JT, Holland AL, et al. Predictors of decline in Alzheimer's disease. Cortex 1991;27:9-17.
30. Ortof E, Crystal HA. Rate of progression of Alzheimer's disease. J Am Geriatr Soc 1989;37:511-514.
31. Haupt M, Pollmann S, Kurz A. Symptom progression in Alzheimer's disease: relation to onset age and familial aggregation: results of a longitudinal study. Acta Neurol Scand 1993;88:349-353.
32. Huff FJ, Growdon JH, Corkin S, Rosen TJ. Age at onset and rate of progression of Alzheimer's disease. J Am Geriatr Soc 1987;35:27-30.
33. Small BJ, Viitanen M, Winblad B, Backman L. Cognitive changes in very old persons with dementia: the influence of demographic, psychometric, and biological variables. J Clin Exp Neuropsychol 1997;19:245-260.
34. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
35. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc 1997;45:321-328.
36. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer's disease: three- and 6-year follow-up of a population-based sample. Arch Neurol 2000;57:839-844.
37. Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992;31:242-249.
38. Storandt M, Morris JC, Rubin EH, Coben LA, Berg L. Progression of senile dementia of the Alzheimer type on a battery of psychometric tests. In: Backman L, ed. Memory functioning in dementia. Amsterdam: Elsevier Science, 1992:207-226.
39. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and APOE genotype. Arch Neurol 1998;155:326-335.
40. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
41. Berg L, Hughes CP, Coben LA, et al. Mild senile dementia of Alzheimer's type: research diagnostic criteria, recruitment, and description of a study population. J Neurol Neurosurg Psychiatry 1982;45:962-968.
42. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
43. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
44. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-1278.
45. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
46. Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983;140:734-739.
47. Wechsler D, Stone CP. Wechsler Memory Scale manual. New York: Psychological Corp., 1973.
48. Benton AL. The Revised Visual Retention Test: clinical and experimental applications. New York: Psychological Corp., 1963.
49. Wechsler D. Wechsler Adult Intelligence Scale manual. New York: Psychological Corp., 1955.
50. Goodglass H, Kaplan E. Boston Naming Test scoring booklet. Philadelphia: Lea & Febiger, 1983.
51. Thurstone LL, Thurstone TG. Examiner manual for the SRA Primary Mental Abilities Test. Chicago: Science Research Associates, 1949.
52. Armitage SG. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol Monogr 1946;60:1-48.
53. Botwinick J, Storandt M. Speed functions, vocabulary ability and age. Percept Mot Skills 1973;36:1123-1128.
54. Storandt M, Hill RD. Very mild senile dementia of the Alzheimer type. II. Psychometric test performance. Arch Neurol 1989;1989:46:383-386.
55. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol 1998;55:395-401.
56. Kanne SM, Balota DA, Storandt M, McKeel DW Jr, Morris JC. Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later. Neurology 1998;50:979-985.
57. SPSS. SPSS user's guide, version 9.0. Chicago: SPSS, 1999.
58. Hogan DB, Thierer DE, Ebly EM, Parhad IM. Progression and outcome of patients in a Canadian dementia clinic. Can J Neurol Sci 1994;21:331-338.
59. Hixson JSE, Vernier DT. Restriction isotyping of human apoliproprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
60. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
61. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
62. SAS Institute. SAS/STAT user's guide, version 6. 4th ed. Cary, NC: SAS Institute, 1990.
63. Anderson RN. Life table for the white population: United States, 1997. Retrieved from Lexis Nexis Statistical Universe (Powertables) from the World Wide Web. Available at: http://www.web.lexis-nexis.com/statuniv.
64. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neruology 1993;43:2457-2465.
65. Locascio JJ, Growdon JH, Corkin S. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol 1995;52:1087-1099.
66. Norwood TH, Smith JR, Stein GH. Aging at the cellular level: the human fibroblastlike cell model. In: Schneider EL, Rowe JW, eds. Handbook of the biology of aging. 3rd ed. San Diego: Academic Press, 1990:131-154.